Anabolic steroidAndrogen19-nortestosteroneAnabolic steroidOralProgestinInvestigational contraceptive

Dimethandrolone Undecanoate

Also known as DMAU · Dimethandrolone undecanoate

Written by enwyReviewed 5 Aug 20261 sources0 comments

Dimethandrolone undecanoate (DMAU) is an orally active, long-chain ester of dimethandrolone (7alpha,11beta-dimethyl-19-nortestosterone) under clinical development as a once-daily male hormonal contraceptive. It combines androgenic and progestogenic activity to suppress gonadotropins, is non-aromatising, and — unusually for an oral androgen — has been evaluated in modern controlled human trials with a comparatively favourable liver profile.

01 Overview

DMAU is one of the leading investigational male oral contraceptives. The undecanoate ester and 11-beta methyl allow meaningful oral bioavailability (taken with food) without a 17-alpha methyl group, so it avoids the classic 17-alpha hepatotoxicity while still profoundly suppressing LH/FSH and testosterone. Phase 1 studies showed marked gonadotropin suppression with generally mild adverse effects (weight gain, acne, modest lipid changes).

It is progestogenic and androgenic, non-aromatising, and not intended for muscle-building; its inclusion here reflects its status as a genuinely studied oral 19-nor androgen. Because suppression is the therapeutic goal, endogenous testosterone recovery after cessation is a key monitored endpoint.

02 Mechanism

Prodrug ester of dimethandrolone, a dual androgen/progestin 19-nor steroid; 11-beta and 7-alpha methyl groups permit oral activity without 17-alpha-alkylation; suppresses gonadotropins.

03 Dosing

Tier	Dose	Route	Notes
Trial contraceptive dosing	100–400 mg/day	Oral	Once daily with food in phase 1 studies.

Ester comparison

Ester	Half-life	Injection freq.	Testosterone by mass

04 Effects

Effect	Magnitude	Evidence
Gonadotropin/testosterone suppressionSuppresses LH/FSH and testosterone — the contraceptive mechanism.	marked	Clinical
Androgenic maintenanceIts own androgenic activity offsets low testosterone during use.	sufficient to avoid hypogonadal symptoms	Clinical

05 Side effects

Effect	Severity	Frequency	Evidence
Weight gain and acneModest weight gain and acne reported in phase 1.	Mild	Common in trials	Clinical
Adverse lipid changesReduced HDL cholesterol observed in trials.	Moderate	Common	Clinical
HPTA suppression (intended)Profound suppression of endogenous testosterone and spermatogenesis.	Severe	Universal (the goal)	Clinical

06 Legal status

United Kingdom

Class C

Anabolic steroid class. · as of Jan 2026

United States

Schedule III controlled

Investigational anabolic steroid; not approved. · as of Jan 2026

07 References

Dimethandrolone undecanoate (DMAU): a potential oral male hormonal contraceptive — phase 1 resultsJournal of Clinical Endocrinology & Metabolism, 2018

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.